Assignee
CELLECTIS SA
FR·13 granted patents·17 pending applications·59 citations·filing 2002–2024
Top patents by PatentIndex Score
30 records- 0188US11690873B2Universal chimeric antigen receptor T cells specific for CD22CELLECTIS SA·Filed 2018·Granted Jul 4, 2023·4 cites·20 claims
- 0286US7098031B2Random integration of a polynucleotide by in vivo linearizationCELLECTIS SA·Filed 2002·Granted Aug 29, 2006·46 cites·40 claims
- 0385US10301614B2Method to overcome DNA chemical modifications sensitivity of engineered tale DNA binding domainsCELLECTIS SA·Filed 2013·Granted May 28, 2019·4 cites·16 claims
- 0484US11944643B2Universal anti-CD22 chimeric antigen receptor engineered immune cellsCELLECTIS SA·Filed 2018·Granted Apr 2, 2024·2 cites·12 claims
- 0581US12133867B2Universal anti-CD22 chimeric antigen receptor engineered immune cellsCELLECTIS SA·Filed 2023·Granted Nov 5, 2024·0 cites·24 claims
- 0679US2025026808A1Universal anti-cd22 chimeric antigen receptor engineered immune cellsCELLECTIS SA·Filed 2024·Application pending·0 cites
- 0777US10508289B2Rare-cutting endonucleases for efficient and specific targeting DNA sequences comprising highly repetitive motivesCELLECTIS SA·Filed 2014·Granted Dec 17, 2019·3 cites·6 claims
- 0866US2025281613A1Enhancing safety of t-cell-mediated immunotherapyCELLECTIS SA·Filed 2023·Application pending·0 cites
- 0965US11578318B2Large volume ex vivo electroporation methodCELLECTIS SA·Filed 2018·Granted Feb 14, 2023·0 cites·8 claims
- 1064US11576317B2Mutant Nicotiana benthamiana plant or cell with reduced XylT and FucTCELLECTIS SA·Filed 2020·Granted Feb 14, 2023·0 cites·20 claims
- 1163US2025057952A1Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumorsCELLECTIS SA·Filed 2022·Application pending·0 cites
- 1262US2025288673A1Gene therapy for the treatment of activated pi3kinase delta syndrome type 1 (apds1)CELLECTIS SA·Filed 2023·Application pending·0 cites
- 1362US2013203840A1Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofCELLECTIS SA·Filed 2012·Application pending·0 cites
- 1462US2026028617A1Tale base editors for gene and cell therapyCELLECTIS SA·Filed 2023·Application pending·0 cites
- 1561US2016273003A1Use of meganucelases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofCELLECTIS SA·Filed 2016·Application pending·0 cites
- 1661US2023416786A1Use of aminoquinoline compounds for higher gene integrationCELLECTIS SA·Filed 2021·Application pending·0 cites
- 1760US2024197880A1New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapyCELLECTIS SA·Filed 2022·Application pending·0 cites
- 1860US2024299453A1GENE THERAPY FOR THE TREATMENT OF HYPER-IgE SYNDROME (HIES) BY TARGETED GENE INTEGRATIONCELLECTIS SA·Filed 2022·Application pending·0 cites
- 1959US2025002945A1New tale protein scaffolds with improved on-target/off-target activity ratiosCELLECTIS SA·Filed 2022·Application pending·0 cites
- 2057US2023279350A1Dual car-t cellsCELLECTIS SA·Filed 2021·Application pending·0 cites
- 2156US11555198B2Method for making nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleasesCELLECTIS SA·Filed 2013·Granted Jan 17, 2023·0 cites·8 claims
- 2256US2023248825A1T-cells expressing immune cell engagers in allogenic settingsCELLECTIS SA·Filed 2021·Application pending·0 cites
- 2355US2020080073A1Dynamic mixing and electroporation chamber and systemCELLECTIS SA·Filed 2019·Application pending·0 cites
- 2454US2013326644A1Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereofCELLECTIS SA·Filed 2013·Application pending·0 cites
- 2554US2023212613A1Methods for targeted insertion of exogenous sequences in cellular genomesCELLECTIS SA·Filed 2021·Application pending·0 cites
- 2652US10738289B2Tevi chimeric endonuclease and their preferential cleavage sitesCELLECTIS SA·Filed 2017·Granted Aug 11, 2020·0 cites·17 claims
- 2752US2023228739A1Method for determining potency of chimeric antigen receptor expressing immune cellsCELLECTIS SA·Filed 2021·Application pending·0 cites
- 2851US12534744B2Methods to genetically modify cells for delivery of therapeutic proteinsCELLECTIS SA·Filed 2021·Granted Jan 27, 2026·0 cites·19 claims
- 2951US11778993B2Repeat variable diresidues for targeting nucleotidesCELLECTIS SA·Filed 2013·Granted Oct 10, 2023·0 cites·13 claims
- 3047US10378007B2Methods for modulating TAL specificityCELLECTIS SA·Filed 2013·Granted Aug 13, 2019·0 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when CELLECTIS SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →